Biex PMA for Salest preterm delivery test slated for second quarter 1997 submission.
This article was originally published in The Gray Sheet
BIEX SALEST PRETERM PREGNANCY TEST SLATED FOR PMA SUBMISSION in the second quarter of 1997, the company says. The Salest test is designed to predict the risk of preterm delivery by measuring salivary estriol (E3), an estrogen hormone produced by the placenta and the fetoplacental unit after the ninth week of gestation.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.